TruCheck Liquid Biopsy

A circulating tumour cell (CTC) blood test for early cancer detection using Datar TruCheck technology. This non-invasive liquid biopsy screens for cancer signals through a standard blood draw, detecting circulating tumour cells before tumours may be visible on conventional imaging.

Liquid biopsy represents one of the most significant advances in cancer screening over the past decade. The TruCheck test, developed by Datar Cancer Genetics, analyses a blood sample for circulating tumour cells (CTCs) — cells that have shed from a primary tumour into the bloodstream. The presence and characteristics of these cells can indicate cancer activity at a stage when the tumour may be too small to detect through conventional imaging methods such as CT or MRI. The test is non-invasive, requiring only a standard venous blood draw. The sample is analysed using molecular characterisation techniques that can identify the tissue of origin for any detected CTCs, providing not just a binary positive or negative result but directional information about where in the body an abnormality may be developing. This information can then guide targeted follow-up imaging and investigation. As a standalone test, TruCheck is positioned for individuals who want to add cancer screening to their health monitoring without committing to a full executive assessment. It is also available as a discounted add-on to the Core or Bespoke Executive Screens for those already undergoing a comprehensive evaluation. The test complements rather than replaces organ-specific cancer screening methods such as mammography, colonoscopy, or PSA testing, offering a broader surveillance layer that covers cancer types for which no routine screening programme exists.